Developer docs
API playgroundTry for free, no card

Search company profiles

Cuorips

Full company profile

uuid0002qr6

Namestring
Cuorips
Legal namestring
Cuorips Inc.
Websiteurl
cuorips.co.jp
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Cuorips Inc. is a Japanese regenerative medicine biotechnology company that researches, develops, and manufactures cell therapy products derived from induced pluripotent stem cells (iPSCs). Founded in 2017 and listed on the Tokyo Stock Exchange Growth Market (TYO:4894) since June 2023, the company's core product is RiHeart (development code IPSOC-1), an allogeneic iPSC-derived cardiomyocyte sheet therapy for patients with severe ischemic heart failure who have exhausted conventional treatment options. RiHeart received conditional and time-limited marketing approval from Japan's Ministry of Health, Labour and Welfare in March 2026, marking it as the world's first approved therapy using cardiomyocytes derived from iPS cells. The therapeutic mechanism combines paracrine signaling and electrical integration of transplanted sheets with host cardiac tissue to support myocardial repair.

The company's technology platform is anchored by proprietary large-scale iPSC cardiomyocyte culture and purification processes developed through a long-standing research partnership with Osaka University. Commercial manufacturing is conducted at the CLiC-1 facility in Minoh, Osaka, which obtained Japan's Specific Cell Processing Product Manufacturing License (FA5210001) in September 2021 and also offers CDMO services to third-party cell therapy developers. Beyond RiHeart, Cuorips maintains a pipeline including catheter-based delivery (with Asahi Intecc and Terumo), expansion into dilated cardiomyopathy indication, and an in vivo regeneration factor inducer program (with Ono Pharmaceutical).

Cuorips generates revenue through product sales of RiHeart to hospitals and medical institutions under Japan's national health insurance reimbursement system (post-March 2026 approval), supplemented by CDMO services via the CLiC-1 facility. Distribution occurs primarily through direct partnerships with leading Japanese university hospitals including Osaka University Hospital, Juntendo University, Tokyo Women's Medical University Hospital, and Kyushu University Hospital. The company operates from Tokyo headquarters with R&D in Suita, manufacturing in Minoh, and a US subsidiary (iReheart Inc.) in Palo Alto for international business development. Strategic shareholders and partners include Daiichi Sankyo, Terumo, Mitsubishi Corporation, Fujifilm, and CellSource.

Short descriptiontext

Cuorips Inc. is a Japanese regenerative medicine biotech developing iPSC-derived cell therapies, with RiHeart — the world's first conditionally approved iPSC-derived cardiomyocyte sheet therapy for severe heart failure — as its core product, serving patients who have exhausted conventional treatments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersChuo, Japan
HQ citystring
Chuo
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative cell therapy, iPSC cardiomyocyte sheets, cell therapy manufacturing, CDMO services, cardiac regenerative medicine
Industry2 codes
PRIMARYHLAAAGAJ
Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Regenerative Cell Therapy
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Product Sales - RiHeart
TypeOne Time License
Description

Revenue from sale of iPSC-derived cardiomyocyte sheet therapy (RiHeart) to hospitals and medical institutions. Treatment received conditional approval in March 2026 under Japan's national health insurance system, enabling reimbursement through national health insurance pricing.

2CDMO Services
TypeProfessional Services
Description

Contract Development and Manufacturing Organization services providing cell therapy manufacturing capabilities to other companies. The company leverages its CLiC-1 facility and expertise in large-scale cell culture.

Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
Pricing details1 tier
1RiHeart Treatment (National Health Insurance)
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing determined through Japan's national health insurance reimbursement system. Not publicly disclosed separately.

GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1RiHeart®
Description

Allogeneic iPS cell-derived cardiomyocyte sheet therapy for severe ischemic heart failure - world's first approved iPSC-derived cardiomyocyte therapy

cuorips.co.jp
+2 more records
Core offering1 text field

Cuorips develops, manufactures, and commercializes regenerative cell therapy products based on induced pluripotent stem cells (iPSCs). Its core commercial product is RiHeart (IPSOC-1), the world's first iPSC-derived allogeneic cardiomyocyte sheet therapy for severe ischemic heart failure, which received conditional approval in Japan in March 2026. The company also operates the CLiC-1 commercial cell processing facility offering contract development and manufacturing (CDMO) services to other cell therapy developers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • World's first iPSC-derived cardiomyocyte sheet therapy approved
Product overview1 text field

Cuorips is a biotechnology company focused on the development, manufacturing, and commercialization of regenerative cell therapy products based on human induced pluripotent stem cells (iPSCs). Its core product is RiHEART/IPSOC-1, the world's first conditionally approved iPSC-derived cardiomyocyte sheet therapy for severe ischemic heart failure, launched in Japan in March 2026. The company also develops a portfolio of iPSC-derived cardiomyocyte patches and related pipeline programs including catheter-based delivery (PJ4) and an in vivo regeneration factor inducer (PJ5). Its commercial-scale CDMO business is anchored by the CLiC-1 manufacturing facility, which provides process development and contract manufacturing services for cell processing products. The company operates globally with subsidiaries in Japan (Cuorips Healthcare Science) and the US (iReheart Inc.).

Product and service3 records
1RiHeart / IPSOC-1 (iPSC-derived Cardiomyocyte Sheet Therapy)
CategoryRegenerative Cell Therapy (Core Product)
Description

An allogeneic iPSC-derived cardiomyocyte sheet therapy (development code IPSOC-1) designed for patients with severe ischemic heart failure who have exhausted conventional treatment options. The sheet is transplanted onto the surface of the heart to support myocardial repair and improve cardiac function through paracrine signaling and electrical integration with the host heart. Conditionally approved in Japan in March 2026 under a 7-year time-limited approval pathway.

2iPSC-derived Cardiomyocyte Patches
CategoryRegenerative Cell Therapy (Core Product)
Description

Cardiomyocyte patches fabricated from human iPSC-derived myocardial cells, transplanted to the heart surface via minimally invasive surgery. The patches induce angiogenesis and facilitate repair of damaged cardiac tissue through paracrine signaling and electrical integration with the host heart.

3CLiC-1 Cell Therapy CDMO Services
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-01
Description

Joint research agreement established in December 2024 for catheter-based delivery of iPSC-derived cardiomyocytes. This partnership advances the company's technology toward minimally invasive heart failure treatment delivery methods.

2Osaka University
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing joint research partnership for iPSC-derived cardiomyocyte technology. Osaka University provided foundational research that led to the world's first iPSC-derived cardiomyocyte sheet therapy.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-development partner under joint R&D contract for cell therapy development. Partnership leverages pharmaceutical industry expertise in drug development and commercialization.

4Mitsubishi Corp.
Strategic tierMinorTypeOthers
Description

Strategic business partnership for commercial expansion and market access within Japan.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Contracted for manufacturing and quality control services for cell therapy production.

Strategic tierMinorTypeOthers
Description

Facility management services for manufacturing and laboratory facilities.

7Cuorips Healthcare Science
Strategic tierCoreTypeOthers
Description

Subsidiary company within the Cuorips group for healthcare and scientific operations.

8iReheart Inc.
Strategic tierCoreTypeOthers
Description

US-based subsidiary headquartered in Palo Alto, California for international business development and potential US market expansion.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Japanese clinical-stage biotech developing iPSC-derived cardiomyocyte cell therapy (HS-001) for heart failure, founded out of Keio University. Direct competitor in the same product category (iPSC-derived cardiomyocytes for severe heart failure) with overlapping clinical trial activity in Japan.

2Terumo Corporation
TypeBroad incumbent
Description

Global medical device company that developed the autologous skeletal myoblast sheet (Heart Sheet) for heart failure, the most direct predecessor product to Cuorips' RiHeart. Also a Cuorips shareholder and delivery technology partner, making it both a peer and a strategic collaborator.

TypeBroad incumbent
Description

Major Japanese pharmaceutical company that is both a co-development partner and early equity investor in Cuorips. Operates broadly in cardiovascular therapeutics and has deep regulatory and commercial reach in Japan that overlaps with Cuorips' target market.

TypeBroad incumbent
Description

Conglomerate with a substantial regenerative medicine / cell therapy CDMO business (FUJIFILM Cellular Dynamics, Japan Tissue Engineering Co.). A Cuorips investor and CDMO ecosystem peer with overlapping capabilities in cell processing and commercial-scale manufacturing.

TypeBroad incumbent
Description

Large Japanese pharmaceutical company with significant investment in cell and gene therapy (including Universal Cells, Xyphos, and partnerships in regenerative medicine). Overlaps with Cuorips as a Japan-based player advancing novel cell-based therapeutics and a potential acquirer or partner.

TypeEmerging player
Description

Clinical-stage cell therapy company developing mesenchymal precursor cell therapies for inflammatory and cardiovascular diseases, including heart failure (Revascor). Comparable as a cell therapy developer targeting the same heart failure indication via a different cell type and mechanism.

TypeEmerging player
Description

China-based biotech developing iPSC-derived cardiomyocyte cell therapy (HiCM-188) for heart failure. Closely comparable to Cuorips' RiHeart in cell type, indication, and approach, representing the most direct international competitor in the iPSC-cardiac space.

TypeEmerging player
Description

French developer of a next-generation left ventricular assist device (LVAD) for advanced heart failure. Competes with Cuorips for the same severe heart failure patient pool via a mechanical rather than biological approach, and is a relevant benchmark for device alternatives in the indication.

TypeRegional player
Description

Japan-based specialty pharmaceutical company with capabilities in biopharmaceuticals and regenerative medicine products, including its approved cell therapy portfolio. Comparable as a domestic Japanese player with regulatory and commercial infrastructure in the cell therapy space.

10Ono Pharmaceutical
TypeOthers
Description

Major Japanese pharmaceutical company and Cuorips' joint development partner on the YS-1301 in vivo regeneration factor inducer program. Relevant as an ecosystem participant and adjacency rather than a direct competitor in cell sheets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cuorips

Regenerative Cell Therapycuorips.co.jp

Cuorips Inc. is a Japanese regenerative medicine biotech developing iPSC-derived cell therapies, with RiHeart — the world's first conditionally approved iPSC-derived cardiomyocyte sheet therapy for severe heart failure — as its core product, serving patients who have exhausted conventional treatments.

What Cuorips does

Cuorips Inc. is a Japanese regenerative medicine biotechnology company that researches, develops, and manufactures cell therapy products derived from induced pluripotent stem cells (iPSCs). Founded in 2017 and listed on the Tokyo Stock Exchange Growth Market (TYO:4894) since June 2023, the company's core product is RiHeart (development code IPSOC-1), an allogeneic iPSC-derived cardiomyocyte sheet therapy for patients with severe ischemic heart failure who have exhausted conventional treatment options. RiHeart received conditional and time-limited marketing approval from Japan's Ministry of Health, Labour and Welfare in March 2026, marking it as the world's first approved therapy using cardiomyocytes derived from iPS cells. The therapeutic mechanism combines paracrine signaling and electrical integration of transplanted sheets with host cardiac tissue to support myocardial repair.

The company's technology platform is anchored by proprietary large-scale iPSC cardiomyocyte culture and purification processes developed through a long-standing research partnership with Osaka University. Commercial manufacturing is conducted at the CLiC-1 facility in Minoh, Osaka, which obtained Japan's Specific Cell Processing Product Manufacturing License (FA5210001) in September 2021 and also offers CDMO services to third-party cell therapy developers. Beyond RiHeart, Cuorips maintains a pipeline including catheter-based delivery (with Asahi Intecc and Terumo), expansion into dilated cardiomyopathy indication, and an in vivo regeneration factor inducer program (with Ono Pharmaceutical).

Cuorips generates revenue through product sales of RiHeart to hospitals and medical institutions under Japan's national health insurance reimbursement system (post-March 2026 approval), supplemented by CDMO services via the CLiC-1 facility. Distribution occurs primarily through direct partnerships with leading Japanese university hospitals including Osaka University Hospital, Juntendo University, Tokyo Women's Medical University Hospital, and Kyushu University Hospital. The company operates from Tokyo headquarters with R&D in Suita, manufacturing in Minoh, and a US subsidiary (iReheart Inc.) in Palo Alto for international business development. Strategic shareholders and partners include Daiichi Sankyo, Terumo, Mitsubishi Corporation, Fujifilm, and CellSource.

Cuorips firmographics

Firmographics
Name
Cuorips
Legal name
Cuorips Inc.
Website
https://cuorips.co.jp
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Cuorips Inc. is a Japanese regenerative medicine biotech developing iPSC-derived cell therapies, with RiHeart — the world's first conditionally approved iPSC-derived cardiomyocyte sheet therapy for severe heart failure — as its core product, serving patients who have exhausted conventional treatments.
Ownership category
akta.pro rank

Cuorips industry classification

Industry
Product category
Regenerative Cell Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAGAJ
Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Regenerative cell therapy
  • IPSC cardiomyocyte sheets
  • Cell therapy manufacturing
  • CDMO services
  • Cardiac regenerative medicine

Where Cuorips is headquartered

Location

Headquarters

HQ city
Chuo
HQ country
Japan
HQ region
Asia

Offices4 records

Markets served

Cuorips business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Product Sales - RiHeart: Revenue from sale of iPSC-derived cardiomyocyte sheet therapy (RiHeart) to hospitals and medical institutions. Treatment received conditional approval in March 2026 under Japan's national health insurance system, enabling reimbursement through national health insurance pricing.
  2. CDMO Services: Contract Development and Manufacturing Organization services providing cell therapy manufacturing capabilities to other companies. The company leverages its CLiC-1 facility and expertise in large-scale cell culture.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goRiHeart Treatment (National Health Insurance)

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Cuorips product offering

Product offering

Core offering

Cuorips develops, manufactures, and commercializes regenerative cell therapy products based on induced pluripotent stem cells (iPSCs). Its core commercial product is RiHeart (IPSOC-1), the world's first iPSC-derived allogeneic cardiomyocyte sheet therapy for severe ischemic heart failure, which received conditional approval in Japan in March 2026. The company also operates the CLiC-1 commercial cell processing facility offering contract development and manufacturing (CDMO) services to other cell therapy developers.

Product overview

Cuorips is a biotechnology company focused on the development, manufacturing, and commercialization of regenerative cell therapy products based on human induced pluripotent stem cells (iPSCs). Its core product is RiHEART/IPSOC-1, the world's first conditionally approved iPSC-derived cardiomyocyte sheet therapy for severe ischemic heart failure, launched in Japan in March 2026. The company also develops a portfolio of iPSC-derived cardiomyocyte patches and related pipeline programs including catheter-based delivery (PJ4) and an in vivo regeneration factor inducer (PJ5). Its commercial-scale CDMO business is anchored by the CLiC-1 manufacturing facility, which provides process development and contract manufacturing services for cell processing products. The company operates globally with subsidiaries in Japan (Cuorips Healthcare Science) and the US (iReheart Inc.).

Differentiator

Problem solved

Functional benefit

Brands

  • RiHeart®: Allogeneic iPS cell-derived cardiomyocyte sheet therapy for severe ischemic heart failure - world's first approved iPSC-derived cardiomyocyte therapy
  • iPS Cardiomyocyte Patches
  • Mini Heart

Products and services

  • RiHeart / IPSOC-1 (iPSC-derived Cardiomyocyte Sheet Therapy) An allogeneic iPSC-derived cardiomyocyte sheet therapy (development code IPSOC-1) designed for patients with severe ischemic heart failure who have exhausted conventional treatment options. The sheet is transplanted onto the surface of the heart to support myocardial repair and improve cardiac function through paracrine signaling and electrical integration with the host heart. Conditionally approved in Japan in March 2026 under a 7-year time-limited approval pathway.
  • iPSC-derived Cardiomyocyte Patches Cardiomyocyte patches fabricated from human iPSC-derived myocardial cells, transplanted to the heart surface via minimally invasive surgery. The patches induce angiogenesis and facilitate repair of damaged cardiac tissue through paracrine signaling and electrical integration with the host heart.
  • CLiC-1 Cell Therapy CDMO Services

Quantifiable outcome

  • World's first iPSC-derived cardiomyocyte sheet therapy approved

Companies that use Cuorips

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Cuorips technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Cuorips partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Stanford UniversitycoreStrategic or Co-development Partner · 1 December 2024Joint research agreement established in December 2024 for catheter-based delivery of iPSC-derived cardiomyocytes. This partnership advances the company's technology toward minimally invasive heart failure treatment delivery methods.
  • Osaka UniversitycoreStrategic or Co-development PartnerLong-standing joint research partnership for iPSC-derived cardiomyocyte technology. Osaka University provided foundational research that led to the world's first iPSC-derived cardiomyocyte sheet therapy.
  • Daiichi SankyocoreStrategic or Co-development PartnerCo-development partner under joint R&D contract for cell therapy development. Partnership leverages pharmaceutical industry expertise in drug development and commercialization.
  • Mitsubishi Corp.minorOthersStrategic business partnership for commercial expansion and market access within Japan.
  • VC Cell TherapyminorImplementation/ SI/ Consulting PartnerContracted for manufacturing and quality control services for cell therapy production.
  • Earth Environmental ServiceminorOthersFacility management services for manufacturing and laboratory facilities.
  • Cuorips Healthcare SciencecoreOthersSubsidiary company within the Cuorips group for healthcare and scientific operations.
  • iReheart Inc.coreOthersUS-based subsidiary headquartered in Palo Alto, California for international business development and potential US market expansion.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Cuorips competitors and assessment

Company assessment

Direct peers

  • Heartseed Inc. Japanese clinical-stage biotech developing iPSC-derived cardiomyocyte cell therapy (HS-001) for heart failure, founded out of Keio University. Direct competitor in the same product category (iPSC-derived cardiomyocytes for severe heart failure) with overlapping clinical trial activity in Japan.

Broad incumbents

  • Terumo Corporation: Global medical device company that developed the autologous skeletal myoblast sheet (Heart Sheet) for heart failure, the most direct predecessor product to Cuorips' RiHeart. Also a Cuorips shareholder and delivery technology partner, making it both a peer and a strategic collaborator.
  • Daiichi Sankyo: Major Japanese pharmaceutical company that is both a co-development partner and early equity investor in Cuorips. Operates broadly in cardiovascular therapeutics and has deep regulatory and commercial reach in Japan that overlaps with Cuorips' target market.
  • FUJIFILM Holdings: Conglomerate with a substantial regenerative medicine / cell therapy CDMO business (FUJIFILM Cellular Dynamics, Japan Tissue Engineering Co.). A Cuorips investor and CDMO ecosystem peer with overlapping capabilities in cell processing and commercial-scale manufacturing.
  • Astellas Pharma: Large Japanese pharmaceutical company with significant investment in cell and gene therapy (including Universal Cells, Xyphos, and partnerships in regenerative medicine). Overlaps with Cuorips as a Japan-based player advancing novel cell-based therapeutics and a potential acquirer or partner.

Emerging players

  • Mesoblast Limited: Clinical-stage cell therapy company developing mesenchymal precursor cell therapies for inflammatory and cardiovascular diseases, including heart failure (Revascor). Comparable as a cell therapy developer targeting the same heart failure indication via a different cell type and mechanism.
  • Help Therapeutics: China-based biotech developing iPSC-derived cardiomyocyte cell therapy (HiCM-188) for heart failure. Closely comparable to Cuorips' RiHeart in cell type, indication, and approach, representing the most direct international competitor in the iPSC-cardiac space.
  • CorWave SA: French developer of a next-generation left ventricular assist device (LVAD) for advanced heart failure. Competes with Cuorips for the same severe heart failure patient pool via a mechanical rather than biological approach, and is a relevant benchmark for device alternatives in the indication.

Regional players

  • JCR Pharmaceuticals: Japan-based specialty pharmaceutical company with capabilities in biopharmaceuticals and regenerative medicine products, including its approved cell therapy portfolio. Comparable as a domestic Japanese player with regulatory and commercial infrastructure in the cell therapy space.

Others

  • Ono Pharmaceutical: Major Japanese pharmaceutical company and Cuorips' joint development partner on the YS-1301 in vivo regeneration factor inducer program. Relevant as an ecosystem participant and adjacency rather than a direct competitor in cell sheets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Cuorips compliance and trust

Trust signal

Compliance1 record

Cuorips financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cuorips leadership team

Management profile

Number of profiles

Profiles9 records

Cuorips subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Cuorips funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cuorips M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cuorips

What does Cuorips do?

Cuorips develops, manufactures, and commercializes regenerative cell therapy products based on induced pluripotent stem cells (iPSCs). Its core commercial product is RiHeart (IPSOC-1), the world's first iPSC-derived allogeneic cardiomyocyte sheet therapy for severe ischemic heart failure, which received conditional approval in Japan in March 2026. The company also operates the CLiC-1 commercial cell processing facility offering contract development and manufacturing (CDMO) services to other cell therapy developers.

Is Cuorips a public or private company?

Cuorips is a public company. It is classified as public and is currently operating.

When was Cuorips founded?

Cuorips was founded in 2017. It employs 11 to 50 people.

Where is Cuorips based?

Cuorips is headquartered in Chuo, Japan, in the Asia region.

How does Cuorips make money?

Two revenue lines are on record. Product Sales - RiHeart is the primary driver. The others are CDMO Services.

Who are Cuorips's main competitors?

Heartseed Inc. is listed as a direct peer. Broad incumbents are Terumo Corporation, Daiichi Sankyo, FUJIFILM Holdings and Astellas Pharma. Emerging players are Mesoblast Limited, Help Therapeutics and CorWave SA. JCR Pharmaceuticals is listed as a regional player. Ono Pharmaceutical is listed as an others.

Does Cuorips have an API?

No public API is recorded for Cuorips.

What industry is Cuorips in?

Cuorips's product category is Regenerative Cell Therapy. Its primary akta.pro industry code is HLAAAGAJ, Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis), with a secondary code of HLAGABAD, Cell Therapy CDMO. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswirePatient recovering well after iPS heart sheet surgery in JapanA woman in her 50s from Kanagawa Prefecture is recovering well after receiving RiHeart, a cardiac muscle sheet from induced pluripotent stem cells, for severe heart failure. The surgery lasted about 50 minutes, and she is scheduled to leave hospital this week. Cuorips Inc. aims to treat 75 patients and demonstrate efficacy by 2033.The Japan TimesAnother iPS product approved for public insurance coverage in JapanJapan's Central Social Insurance Medical Council approved public health insurance coverage for RiHeart, an iPS cell-derived cardiac muscle sheet, effective Sept. 1. The product, developed by Cuorips, is priced at ¥53.2 million ($326,400) with out-of-pocket costs capped. The health ministry will decide on full-scale approvals after seven years of additional data.The AustralianJapan’s iPSC milestone lifts Cynata focusJapan's Ministry of Health, Labour and Welfare granted conditional approval for two induced pluripotent stem cell (iPSC) therapies developed by Sumitomo Pharma and Cuorips, marking the first regulatory validation of this technology. Cynata Therapeutics views this milestone as significant for its Cymerus platform, which utilizes iPSCs to manufacture mesenchymal stem cells for ongoing clinical trials in knee osteoarthritis and acute graft-versus-host disease.Medical and health informationJapan gives green light to first-of-their-kind stem cell therapiesJapan has granted world-first conditional approval for two stem cell-based regenerative therapies: AMCHEPRY for Parkinson's disease, developed by Sumitomo Pharma, and RiHEART for severe heart failure, developed by biotech startup Cuorips. Both therapies use induced pluripotent stem cells (iPSCs) and were approved under Japan's Conditional and Time-Limited Approval pathway, which allows treatments to reach patients while additional safety and effectiveness data continue to be collected. The approvals were based on small clinical trials—one with 7 Parkinson's patients showing symptom improvements over two years, and another with 8 heart failure patients demonstrating improved exercise tolerance—though experts caution that evidence remains limited due to small sample sizes and short observation periods.ScienceAlertStem Cell Treatments For Parkinson's And Heart Failure Approved in World FirstJapan has approved the world's first commercially available stem cell treatments for Parkinson's disease and severe heart failure, with products from Sumitomo Pharma and Cuorips expected to reach patients by summer. The approvals cover Amchepry, which uses iPS cells to treat Parkinson's, and ReHeart, a therapy developed by Cuorips to restore heart function.The HinduJapan approves stem-cell treatment for Parkinson's in world firstJapan's health ministry has approved two groundbreaking stem-cell treatments using induced pluripotent stem (iPS) cells: Amchepry by Sumitomo Pharma for Parkinson's disease and ReHeart by medical startup Cuorips for severe heart failure. The therapies, expected to reach patients as early as this summer, represent the world's first commercially available medical products using iPS technology. Health Minister Kenichiro Ueno stated the approvals aim to bring relief to patients not only in Japan but globally, with the treatments receiving conditional time-limited approval based on limited clinical trial data.Gadgets 360Japan Approves Stem-Cell Treatment For Parkinson's In World FirstJapan has approved groundbreaking stem-cell treatments for Parkinson's disease and severe heart failure, making them the world's first commercially available medical products using induced pluripotent stem (iPS) cells. Sumitomo Pharma received conditional approval for Amchepry, its Parkinson's treatment that transplants stem cells into patients' brains, while medical startup Cuorips was approved for ReHeart heart muscle sheets, with rollout to patients expected as early as this summer.AsahiJapan approves world‑first iPS cell drugs for summer releaseJapan approved the world's first iPS cell-based regenerative medical products on March 6, with Health Minister Kenichiro Ueno granting provisional certification to ReHeart for severe heart failure and Amchepry for Parkinson's disease. The treatments, developed by Cuorips Inc. and Sumitomo Pharma Co. respectively using third-party iPS cells stocked by Kyoto University's CiRA Foundation, could be available to patients as early as this summer under Japan's national health insurance system. Both products are approved under a conditional and time-limited system requiring seven-year follow-up studies for full approval.